Revenue Recognition (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) distributor obligation	Dec. 31, 2020 USD ($) distributor	Dec. 31, 2019 USD ($) distributor
Disaggregation of Revenue [Line Items]
Provision for revenue reserves to reduce product revenues to product revenues, net			$ 247,100	$ 202,200	$ 105,900
Upfront payment receivable	$ 88,000		88,000
Licensing revenue			194,134	83,138	$ 69,888
Prepaid expenses and other current assets	16,611		16,611	8,310
Santen
Disaggregation of Revenue [Line Items]
Repayment of upfront payment upon termination, amount	8,000
Collaborative Arrangement
Disaggregation of Revenue [Line Items]
Supplemental upfront payment receivable	$ 2,000		$ 2,000
First Santen Agreement
Disaggregation of Revenue [Line Items]
Upfront payment receivable		$ 50,000
Contingent payments receivable upon achievement of development and regulatory milestones (up to)		39,000
Contingent payments receivable upon achievement of commercial milestones (up to)		$ 60,000
First Santen Agreement | Santen
Disaggregation of Revenue [Line Items]
Royalty percentage (in excess of)		25.00%
Company's share of clinical trial costs, percentage		50.00%
Collaborative agreement, termination by counterparty, effective after written notice period		180 days
Collaborative agreement expiration, period after first commercial sale of product	3 years
Repayment of upfront payment upon termination, percentage		85.00%
Reimbursement of development expenses upon termination, percentage		50.00%
Number of performance obligations | obligation			2
Period before first commercial sale of product for company to enter manufacturing and supply agreement			24 months
Second Santen Agreement | Santen
Disaggregation of Revenue [Line Items]
Upfront payment receivable	$ 88,000	$ 50,000	$ 88,000
Contingent payments receivable upon achievement of development and regulatory milestones (up to)	15,500		15,500
Contingent payments receivable upon achievement of commercial milestones (up to)	60,000		60,000
Supplemental upfront payment receivable	$ 2,000		$ 2,000
Collaborative agreement, termination by counterparty, effective after written notice period	180 days
Collaborative agreement expiration, period after first commercial sale of product	3 years
Number of performance obligations | obligation			2
Licensing revenue			$ 82,000
Deferred revenue, non-current	$ 56,300		56,300	$ 50,800
Prepaid expenses and other current assets	6,300		6,300
Additional amount receivable, upon execution of collaboration agreement	$ 2,000		2,000
Second Santen Agreement | Expanded Territories Excluding China and India | Santen
Disaggregation of Revenue [Line Items]
Royalty percentage (in excess of)	25.00%
Second Santen Agreement | China and India | Santen
Disaggregation of Revenue [Line Items]
Royalty percentage (in excess of)	20.00%
Second Santen Agreement | Europe | Santen
Disaggregation of Revenue [Line Items]
Licensing revenue			80,000
Deferred revenue, non-current	$ 8,000		$ 8,000
Customer Concentration Risk | Sales Revenue, Net | Rhopressa And Rocklatan
Disaggregation of Revenue [Line Items]
Number of distributors | distributor			3	3	3
Customer Concentration Risk | Sales Revenue, Net | Rhopressa And Rocklatan | Distributor One
Disaggregation of Revenue [Line Items]
Concentration risk percentage			36.90%	37.40%	36.50%
Customer Concentration Risk | Sales Revenue, Net | Rhopressa And Rocklatan | Distributor Two
Disaggregation of Revenue [Line Items]
Concentration risk percentage			31.00%	32.40%	33.30%
Customer Concentration Risk | Sales Revenue, Net | Rhopressa And Rocklatan | Distributor Three
Disaggregation of Revenue [Line Items]
Concentration risk percentage			30.90%	28.80%	28.00%